Transcutaneous Auricular Vagus Nerve Stimulation for Meniere Disease

NACompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

January 1, 2022

Study Completion Date

May 1, 2022

Conditions
Meniere Disease
Interventions
OTHER

Transcutaneous Auricular Vagus Nerve Stimulation with Betahistine

"Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on the left ear was selected and stimulated with electronic acupuncture apparatus (Hwato, SDZ-IIB), with continuous wave, 25 Hz in frequency, 4 to 8 mA in intensity depending on patient's tolerance. The first 3 treatments were conducted in hospital, during which, the patients were trained to use the apparatus under the instruction of research staff. Afterwards, the rest treatments were exerted at home, twice a day, after every breakfast and dinner respectively, 30 min each time. The treatment was given from Monday to Friday a week, totally for 12 weeks.~Participants received betahistine mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day."

Trial Locations (1)

Unknown

Beijing TongRen Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Tongren Hospital

OTHER

NCT05328895 - Transcutaneous Auricular Vagus Nerve Stimulation for Meniere Disease | Biotech Hunter | Biotech Hunter